Results: 67

Associação de variáveis sociodemográficas e clínicas com os tempos para início do tratamento do câncer de próstata

Resumo Disparidades na atenção ao câncer de próstata têm sido reveladas e associadas a fatores sociodemográficos e clínicos, os quais determinam os tempos para diagnóstico e início do tratamento. O objetivo deste artigo é avaliar a associação de variáveis sociodemográficas e clínicas com o...

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?

Int. braz. j. urol; 45 (4), 2019
ABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TR...

Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions

Int. braz. j. urol; 45 (4), 2019
ABSTRACT Purpose To determine if PSAD, PSADtz, and ADC values improve the accuracy of PI-RADS v2 and identify men whose concurrent systematic biopsy detects clinically significant cancer on areas without mpMRI visible lesions. Materials and methods Single reference-center, cross-sectional, retrospecti...

Prostate cancer screening in low- and middle- income countries: the Mexican case

Salud pública Méx; 61 (4), 2019
Abstract: Prostate-specific antigen (PSA)-based early detection for prostate cancer is the subject of intense debate. Implementation of organized prostate cancer screening has been challenging, in part because the PSA test is so amenable to opportunistic screening. To the extent that access to cancer scr...

Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?

Int. braz. j. urol; 45 (3), 2019
ABSTRACT Purpose: 68Ga-PSMA PET/CT imaging is a promising modality for the staging of recurrent prostate cancer (PCa). Current evidence suggests limited diagnostic value of the 68Ga-PSMA PET/CT in PSA-levels ≤0.3ng/mL. Experimental data have demonstrated an increase in PSMA-expression in PCa metas...

Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy

Int. braz. j. urol; 45 (3), 2019
ABSTRACT Introduction: To determine the impact of time from biopsy to surgery on outcomes following radical prostatectomy (RP) as the optimal interval between prostate biopsy and RP is unknown. Material and methods: We identified 7, 350 men who underwent RP at our institution between 1994 and 2012 and ...

A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?

Int. braz. j. urol; 45 (3), 2019
ABSTRACT Purpose: To evaluate the trend of use of Prostate Specific Antigen (PSA) for screening of prostate cancer (PC) among Brazilian doctors, from the beginning of its regular availability in clinical laboratories. Material and Methods: A serial cross-sectional study was performed using data obtaine...

Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?

Int. braz. j. urol; 45 (2), 2019
ABSTRACT Objective: To build a model to evaluate the impact of salvage radiotherapy (SRT) in men with PSA rise or persistent PSA after undergoing radical prostatectomy (RP). Materials and Methods: The study included 107 node-negative patients treated with SRT after RP at a single institution. Patients ...

Can expressed prostatic secretions affect prostate biopsy decision of urologist?

Int. braz. j. urol; 45 (2), 2019
ABSTRACT Objectives: To evaluate the frequency of NIH category IV prostatitis, and the use of expressed prostatic secretions tests in an effort to improve the reliability of prostate specific antigen as an indicator, to avoid unnecessary prostate biopsy. Materials and Methods: 178 expressed prostatic s...

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 - 100 ng / mL

Int. braz. j. urol; 45 (1), 2019
ABSTRACT Introduction: Prostate - specific antigen (PSA) is a useful biomarker for detection of prostate cancer (PCa) and for risk classification in addition to TNM classification and Gleason score (GS). We reported the role of PSA in patients with low (< 20 ng / mL) and extremely high (≥ 100 n...